Member Info for Bermudashorts

Inanaco,

The wording from Immatic's own press announcement is perhaps a little clearer:-

'Under the terms of the agreement, Immatics will receive an upfront payment of 45 Million € (~$50 million) for two initial programs and is eligible to receive over $550M in development, regulatory and commercial milestone payments for each product as well as additional royalty payments.'

http://immatics.com/press-release/immatics-and-gsk-partner-to-develop-novel-adoptive-cell-therapies.html

Inanaco,

The upfront payment isn't per target - it's for the whole deal.

Scancell's peer and one-time collaborator Immatics seem to be going from strength to strength with a GSK TCR collaboration announced today. Total potential value of the deal is €550 plus milestones including an upfront payment of €46m. This sentence regarding timescales was interesting and perhaps relevant here:-

'Immatics will be responsible for developing the therapies up to the point of selecting a candidate for clinical development, which could take anywhere between 36 and 42 months, according to Harpreet Singh, CEO of Immatics'

https://www.labiotech.eu/car-t/gsk-immatics-tcr/

Thanks Bronxville and Ivy

Should have added that the post below is to hex314

I agree that it may well take a couple of years to complete preclinical development for AP103. I may have misunderstood your posts, but it appears you are suggesting that proof of concept studies are required before AP103 can be taken into a phase I clinical trial. That's not the case, a proof of concept clinical trial IS a phase I/IIa trial.

I'm not sure the IND will make any difference to whether or not Scancell can persuade any other health authorities in the UK to cover the cost of Keytruda.

According to the Clinical Trials Register (European) the original intention was to open 2 sites in the UK but it's clearly taking a long while to negotiate costs for the second. I can understand that it's complicated when a particular hospital or health authority may already be running fully funded combination clinical trials and may be wary of creating issues or setting a precedent. There are so many combination trials and presumably most NHS hospitals have no difficulty in providing opportunities for their patients to take part in trials that are fully paid for by the sponsor.

It's much simpler in the US. Obama's Affordable Care Act introduced a mandatory requirement for insurers to not only allow patients to participate in clinical trials,but also to cover the costs of any standard of care treatments. So it's just not an issue over there - the insurers are legally obliged to pay for the Keytruda.

Chelsea,

Thanks for your reply. I think that we could/should hear very soon that the first patient in the UK has been dosed. It obviously will take longer in the US but I'd really hope for a comprehensive update from Scancell to confirm the number and locations of the study centres and names of the investigators in the US, together with a timeframe for when they hope to be up, running and recruiting.

Re. your 17.25 and dosing first SCIB1 patient - has the timeline of Q3 come from Scancell or is it just what you're hoping for?

Further extension has been granted until 5pm on 28th February - see RNS

https://www.londonstockexchange.com/exchange/news/market-news/market-news-detail/REDX/14424613.html

An interesting paper from University Medical Center Hamburg-Eppendorf was published today in Cancers Journal. Essentially it's a thorough and in depth evaluation of the Parsortix system on behalf of the EU/IMI CANCER-ID consortium. Some sound bites:-

'The established workflow will contribute to supporting the use of size-based CTC enrichment platforms in clinical trials testing the clinical validity and utility of CTCs for personalized medicine. '

'The CANCER ID consortium funded by the European Innovative Medicine Initiative (IMI), aimed to close this gap and validate innovative CTC detection approaches for future clinical trials. This standardization of novel technologies and workflows is much needed to increase the acceptance of CTCs as biomarkers in the clinic.'

'The Parsortix® system (ANGLE plc)-a size-based enrichment device - has been introduced to the CTC field and shown promising results across multiple tumor entities [19,20,21,22,23,24]. In addition to enumeration, the device has demonstrated its capabilities in isolating rare CTC clusters [24,25] and preserving cell viability following CTC enrichment '

Conclusions

Extensive examinations of pre-analytical and analytical variables using the label-independent Parsortix® system were performed in this study. Initial experimental results with spiked tumor cell line cells were cross-validated with clinical cancer patient samples and resulted in the identification of robust workflows for CTC detection utilizing this enrichment platform.

Depending on the nature of further downstream analysis, a combination of either EDTA blood samples with medium separation pressure or TransFix® preservative tubes with high separation pressure lead to optimal CTC detection from whole blood. Intact tumor cell morphology was maintained, as confirmed via immunocytochemical staining for both workflows. Furthermore, whole genome amplification on a single cell basis, a prerequisite for multiple downstream analyses, was highly efficient. Therefore, the established standardized workflows enable the enrichment of viable or fixed CTCs and allow for precise enumeration and successful downstream analysis of patient-derived CTCs.

Https://www.mdpi.com/2072-6694/12/2/442/htm#

Thanks, looks like only 4 of the companies were presenting - Mogrify, Arjuna, Evonetix and Enesi. No worries.

As you say, let's hope it was a successful trip and his diary was packed.

Crumbs,
Are you sure he actually was presenting? Only had a quick look but I couldn't find any mention of a presentation and assumed he was just attending for the one to one meetings and networking.

5th on the list

Myalept Produced by the international Amryt Pharma, Myalept treats generalized lipodystrophy, a condition that removes virtually all the fat from a person’s body affecting the production of leptins — a hormone in the small intestine that helps regulate energy levels and determines hunger. It comes in a powder form, and is meant to be mixed with sterile water for each dose. Just one of these doses costs $6,412 which, at the necessary 30 doses a month, adds up to $192,335.

https://www.healthing.ca/pharma/the-worlds-10-most-expensive-drugs

So sorry to read your 19.38 and wish your daughter-in-law all the very best.

Summit receives its first milestone payment from Eurofarma:-

'Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) today announced that it achieved the first milestone under its license and collaboration agreement with Eurofarma Laboratórios SA (‘Eurofarma’). The $1.0 million milestone payment was triggered by Summit achieving its initial patient enrolment target at trial sites in Latin America in the Phase 3 clinical trials of ridinilazole for C. difficile infection (‘CDI’). '

http://www.globenewswire.com/news-release/2020/02/06/1980937/0/en/Summit-Therapeutics-to-Receive-1-0-Million-Milestone-Payment-from-Eurofarma.html

Idiot441,

R&D tax credits can be in the form of corporation tax relief but loss making companies can take a cash payment instead. Given the nature of their work, most biotech. companies are loss making during the early years and take R&D tax credits as a cash payments to boost cash flow.

Yes, a healthy £20.4 million cash balance as at Oct 2019 but also an additional £3m due in R&D tax credit.

The Clinical Trials Register has been updated for both Ri-CoDIFy trials.

Ri-CoDIFy 1 is now recruiting in 133 locations and Ri-CoDIFy 2 in 87. Centres have opened in several previously unlisted countries including Belarus, Belgium, Brazil, Bulgaria, Czechia, Chile, Germany, Greece, Hungary, Korea, Mexico, Peru, Poland Russia and Spain.

Truly a global trial with an impressive number of study centres now open for recruitment - hopefully will inject some pace into the speed of recruitment.

Tremendous news for Summit.

' Biomedical Advanced Research and Development Authority (‘BARDA’) has expanded its award for the clinical and regulatory development of Summit’s precision antibiotic ridinilazole for the treatment of C. difficile infection (‘CDI’) by $8.8 million. The additional funding is being provided to support a new clinical trial in adolescent patients and brings the total value of the award to up to $72.5 million'